74,225 results match your criteria Acute Myeloid Leukemia Not Otherwise Categorized


Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.

Exp Mol Pathol 2019 Apr 17. Epub 2019 Apr 17.

Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America. Electronic address:

KIT mutations are observed in about 20-40% of acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 [abbreviated AML t(8;21) here] with mutations involving exon 17 being the most common. Despite high frequencies of KIT mutations in both AML t(8;21) and systemic mastocytosis (SM), AML t(8;21) associated with SM is uncommon, and restricted to KIT exon 17 mutated cases. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00144800193021
Publisher Site
http://dx.doi.org/10.1016/j.yexmp.2019.04.009DOI Listing
April 2019
1 Read

Clonal haematopoiesis and risk of acute myeloid leukemia.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Washington University School of Medicine;

Nearly all adults harbor acute myeloid leukemia-related clonal hematopoietic mutations at a variant allele fraction of ≥0.0001, yet relatively few develop hematologic malignancies. We conducted a nested analysis in the Nurses' Health Study and Health Professionals Follow-Up Study blood subcohorts, with up to 22 years of follow-up, to investigate associations of clonal mutations of ≥0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.215269DOI Listing
April 2019
2 Reads

Evolutionary trajectory of leukemic clones and its clinical implications.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Weizamnn Institute of scirence

Acute Myeloid Leukemia's ontogeny is a multistep process. It is driven both by features of the malignant clone itself, as well as by environmental pressures, making it a unique process in each individual. Recent years' technological advancements have increased our understanding about the steps that take place at the genomic level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.195289DOI Listing

Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Department of Internal Medicine, Section of Hematology, Yale School of Medicine;

Immunosuppressive therapy is one therapy option for treatment of patients with lower-risk myelodysplastic syndromes. However, the use of several different immunosuppressive regimens, the lack of high-quality studies, and the absence of validated predictive biomarkers pose important challenges. We conducted a systematic review and meta-analysis according to the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines and searched MEDLINE via PubMed, Ovid EMBASE, COCHRANE registry of clinical trials (CENTRAL), and the Web of Science without language restriction from inception through September 2018 as well as relevant conference proceedings and abstracts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.219345DOI Listing

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia - results from an international collaborative study.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.

Acute myeloid leukemia with t(6;9)(p22;q34) is a distinct entity accounting for 1-2% of acute myeloid leukemia cases. A substantial proportion of these patients have a concomitant FLT3-ITD. While outcomes are dismal with intensive chemotherapy, limited evidence suggests allogeneic hematopoietic cell transplantation may improve survival if applied early during first complete remission. Read More

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2018.208678DOI Listing
April 2019
1 Read

Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling.

Authors:
Vijaya Raj Bhatt

Cancer Treat Rev 2019 Apr 11;75:52-61. Epub 2019 Apr 11.

Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE, United States; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, United States. Electronic address:

Acute myeloid leukemia (AML) presents therapeutic challenges in older adults because of high-risk leukemia biology conferring chemoresistance, and poor functional status resulting in increased therapy-related toxicities. Recent FDA approval of 8 new drugs for AML has increased therapeutic armamentarium and also provides effective low-intensity treatment options. Rational therapy selection strategies that consider individual's risk of therapy-related toxicities and probability of disease control can maximize benefits of available treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2019.04.001DOI Listing

Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia.

Leuk Res 2019 Apr 9;81:27-34. Epub 2019 Apr 9.

Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, 1081HV Amsterdam, the Netherlands. Electronic address:

Leukemic stem cells (LSCs), defined by CD34/CD38 expression, are believed to be essential for leukemia initiation and therapy resistance in acute myeloid leukemia. In addition, the side population (SP), characterized by high Hoechst 33342 efflux, reflecting therapy resistance, has leukemia initiating ability. The purpose of this study is, in both CD34-positive and CD34-negative AML, to integrate both types of LSC compartment into a new more restricted definition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.04.004DOI Listing

Ailanthone up-regulates miR-449a to restrain acute myeloid leukemia cells growth, migration and invasion.

Exp Mol Pathol 2019 Apr 16. Epub 2019 Apr 16.

Department of Hepatobiliary Surgery, Jining No.1 People's Hospital, Jining 272000, Shandong, China. Electronic address:

Background: Ailanthone (AIL) is a quassinoid isolated from traditional Chinese herbal medicine Ailanthus altissima. The anti-tumor activities of AIL have been reported in various solid tumors. This study aimed to reveal the in vitro effect of AIL on acute myeloid leukemia (AML) cells. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00144800183050
Publisher Site
http://dx.doi.org/10.1016/j.yexmp.2019.04.011DOI Listing
April 2019
1 Read

LncRNA HOTTIP promotes proliferation and cell cycle progression of acute myeloid leukemia cells.

Eur Rev Med Pharmacol Sci 2019 Apr;23(7):2908-2915

Department of Pediatrics, The Second People's Hospital of Liaocheng, Linqing, China.

Objective: The aim of this study was to elucidate the biological function of long non-coding RNA (lncRNA) HOTTIP (HOXA transcript at the distal tip) in the development of acute myeloid leukemia (AML), and to investigate the potential mechanism.

Patients And Methods: Relative expression levels of HOTTIP, microRNA-608 and DDA1 in AML patients were determined by quantitative Real-time polymerase chain reaction (qRT-PCR). Meanwhile, the expressions of these genes in AML cell lines were detected as well. Read More

View Article

Download full-text PDF

Source
http://www.europeanreview.org/article/17569
Publisher Site
http://dx.doi.org/10.26355/eurrev_201904_17569DOI Listing
April 2019
1 Read

Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group.

Mod Pathol 2019 Apr 18. Epub 2019 Apr 18.

Department of Pathology and Laboratory Medicine, University of Chicago, Chicago, IL, USA.

Acute undifferentiated leukemia is a rare type of acute leukemia that shows no evidence of differentiation along any lineage. Clinical, immunophenotypic and genetic data is limited and it is uncertain if acute undifferentiated leukemia is biologically distinct from acute myeloid leukemia with minimal differentiation, which also shows limited myeloid marker expression and has been reported to have a poor prognosis. We identified 92 cases initially diagnosed as acute undifferentiated leukemia or acute myeloid leukemia with minimal differentiation from pathology databases of nine academic institutions with available diagnostic flow cytometric data, cytogenetic findings, mutational and clinical data. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41379-019-0263-3
Publisher Site
http://dx.doi.org/10.1038/s41379-019-0263-3DOI Listing
April 2019
1 Read

BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition.

Cell Death Dis 2019 Apr 18;10(5):338. Epub 2019 Apr 18.

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Vico L. De Crecchio 7, 80138, Napoli, Italy.

Leukemia is characterized by genetic and epigenetic mutations resulting in selection of cancer cells, which are unable to differentiate. Although genetic alterations are difficult to target, the epigenome is intrinsically dynamic and readily offers new therapeutic strategies. Thus, identifying cancer-specific context-dependent targets and unraveling their biological function may open up new therapeutic perspectives. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-019-1570-9DOI Listing

Cannibalistic acute myeloid leukemia with ZMYND11-MBTD1 fusion.

Blood 2019 Apr;133(16):1789

Hospices Civils de Lyon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2019-01-898619DOI Listing

Analysis of preventability of malignancy related maternal death from the nationwide registration syste19m of maternal deaths in Japan.

J Matern Fetal Neonatal Med 2019 Apr 18:1-191. Epub 2019 Apr 18.

b Department of Obstetrics and Gynecology , Mie University School of Medicine , Mie , Japan.

Objective: We reviewed malignancy related maternal deaths in Japan to ascertain if there were avoidable factors.

Methods: Malignancy related maternal death in Japan reported to the Maternal Death Exploratory Committee, from 2010 to 2016 inclusive.

Results: There were 12 cases of maternal death caused by malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14767058.2019.1609930DOI Listing

Frequency of hematologic and solid malignancies in the family history of 50 patients with acute myeloid leukemia - a single center analysis.

PLoS One 2019 18;14(4):e0215453. Epub 2019 Apr 18.

Department of Medicine III, University Hospital Munich, Ludwig-Maximilians-University Munich-Campus Großhadern, Munich, Germany.

Background And Objective: The revised World Health Organization classification of 2016 for myeloid neoplasms and acute leukemia added a section of myeloid neoplasms with germline predisposition. The main objective of our study was to evaluate the frequency of hematologic and solid malignancies in the family history of patients with acute myeloid leukemia (AML) by using a systemic pedigree interview. The family history was taken of 50 patients between 24 and 80 years. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0215453PLOS
April 2019
1 Read

[Recent Advances in Immunotherapy for Acute Myeloid Leukemia --Review].

Authors:
Bin Xu Yi Xiao

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):633-636

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China E-mail:

Currently, the traditional chemotherapeutic drugs for acute myeloid leukemia (AML) showed significant curative efficacy, including the improving long-term prognosis and the life quality of the patients, however the traditional chemotherapeuatic drugs showed the some limitatious in the aspects of enhancing the complete remission rate of newly diagnosed AML patients, overcoming the relapse after remission,as well as the primary and secondary drug-resstance to chemotherapeutics. In order to improve the long-term prognisis of patients, the immuno therapy will the best choice for these patients. This review sammarizes the main current advance of immunotherapy of AML at home and abroad, such as antibody-drug conjugate(ADC), bispecific T cell engager (BiTE), chimeric type of antigen receptor T cell (CAR-T) therapy, checkpoint inhibitors; dendritic cell vaccination and peptide vaccines; natural killer cell (NK) therapy and so on. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn1009-2137.2019.02.053DOI Listing
April 2019
2 Reads

[Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):494-503

Fujian Institute of Hematology,Fujian Provincial Key Laboratory on Hematology,Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China.

Objective: To systematically evaluate the efficacy and safety of DCAG regimen for treating the intermediate or high risk MDS and AML.

Methods: PubMed, EMbase, The Cochrane Library, WanFang Data and CNKI databases were searched to collect randomized controlled trials (RCTs) of decitabine combined with CAG regimen for intermediate or high risk MDS and AML from inception to March, 2018. The quality of each RCT was evaluated by the Cochrane collaboration´s tool for assessing the risk of bias. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.030DOI Listing
April 2019
2 Reads

[Effects of a Traditinal Chinese Medicine Compound Regimen on Differentiation and Proliferation of Acute Myeloid Leukemia Cell Lines].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):403-408

Laboratory for Stem Cell and Regenerative Medicine,Affiliated Hospital of Weifang Medical College, Weifang 261042, Shandong Province,

Objective: To study the effect of traditional chinese medicine (TCM) compound on myeloid leukemia cells and to explore its anti-leukemic mechanism.

Methods: Myeloid leukemia cell lines were cultured in vitro and treated with TCM compound. The proliferation of the leukemia cells was measured by CCK8 method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.015DOI Listing
April 2019
1 Read

[Efficacy, Prognosis and Safety of Decitabine Combined with Low-Dose Cytarabine in the Treatment of Elderly Patients with Relapsed/Refractory Acute Myeloid Leukemia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):390-395

Department of Hematology, Yinzhou Hospital Affiliated to Ningbo University, Ningbo 315105, Zhejiang Province, China.

Objective: To investigate the efficacy, prognosis and safety of decitabine combined with low-dose CAG regimen in the treatment of elderly patients with acute myeloid leukemia (AML).

Methods: The clinical data of 40 elderly patients with relapsed/refractory AML (69-85 years old) admitted to our hospital from January 2014 to August 2016 were analyzed retrospectively. 40 patients were divided into combination therapy group and CAG group according to different treatment methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.013DOI Listing
April 2019
1 Read

[Effect of Mangiferin on Proliferation of FLT3-ITD Mutation Positive Acute Myeloid Leukemia Cell MV4-11 and Its Mechanism].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):385-389

Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.

Objective: To investigate the effects of mangiferin on proliferation, apoptosis and cycle of FLT3-ITD mutation-positive acute myeloid leukemia cells and its mechanism.

Methods: The effects of different concentration of mangiferin on proliferation of MV4-11 cells were detected by CCK8 method. Apoptosis, cell cycle and FLT3 transmembrane protein expression were detected by flow cytometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.012DOI Listing
April 2019
1 Read

[Expression and Clinical Significance of PD-L1 and MicroRNA-138-5p in Patients with Acute Myeloid Leukemia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):373-378

Center of Clinical Laboratorial Medicine,The First Affiliated Hospital of Jinan University,Guangzhou 510630, Guangdong Province, China,E-mail:

Objective: To investigate the expression and clinical significance of PD-L1 and microRNA-138-5p in the peripheral blood mononuclear cells of patients with acute myeloid leukemia.

Methods: The SYBR GreenⅠreal-time PCR was used to detect the expression levels of PD-L1 mRNA and miR-138 in 20 cases of primary AML, 9 cases of relapsed/refractory AML and 8 cases of complete remission. The samples of peripheral blood of 20 healthy peoples were used as controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.010DOI Listing
April 2019
2 Reads

[NPM1 High Mutant Allele Burden is an Adverse Prognostic Factor for AML Patients with Mutated NPM1].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):365-372

Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.

Objective: To investigate the clinical features, accompanying gene mutation characteristics and prognostic factors of adult patients with acute myeloid leukemia with mutated NPM1 (NPM1AML).

Methods: Seventy-three patients with newly diagnosed adult NPM1AML were selected. The mutations of 22 genes were detected by second generation sequencing and 43 fusion genes of AML were detected by real-time fluorescent quantitative PCR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.009DOI Listing
April 2019
2 Reads

[Clinical Efficacy of Modified BU/CY as Conditioning Regimen Combined with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Young Acute Myeloid Leukemia Patients with Low or Intermediate Risk].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):360-364

Second Clinical College, Shanxi Metical University; Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China,E-mail:

Objective: To investigate the safety and efficacy of autologous peripheral blood hematopoietic stem cell transplantation (auto-PBHSCT) using modified BU/CY conditioning regimen for young AML patients of low and middle risk in the first complete remission (CR1).

Methods: Ten young AML patients of low and middle risk who did not want to accept allogeneic hematopoietic stem cell transplantation(allo-HSCT)and underwent auto-PBHSCT in CR1 during May 2013 to December 2016 were retrospectively analyzed. From 3 months after auto-PBHSCT, the maintenance therapy with interleukin-2 (IL-2) or IL-2 combined with histamine dihydrochloride was performed for these patients in the next 18 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.008DOI Listing
April 2019
2 Reads

[Clinical Characteristics of Patients with Ph Mixed Phenotype Acute Leukemia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):354-359

Blood Diseases Hospital, Institute of Hematology, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin 300020

Objective: To investigate the clinical biological characteristics and prognosis of the patients with mixed phenotype acute leukemia with t(9;22)(q34;q11.2) and/or BCRABL1 (Ph MPAL).

Methods: The morphological, immunological, cytogenetic, and molecular features of 33 in patients with Ph MPAL were retrospectively analyzed in our center from June 2002 to June 2016 according to the scoring proposal of European Group for the Classification of Acute Leukemia(EGIL )1998 and WHO 2008 criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.007DOI Listing
April 2019
2 Reads

[Mutation Spectrum of FANCJ Gene in Adult Acute Myeloid Leukemia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):348-353

Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China,E-mail:

Objective: To detect and analyze the mutation status of FANCJ gene in adult AML patients, so as to provide the basis for studying the mechanism of FANCJ driven AML and guiding the preventim and treatment of deseese.

Methods: The cDNAs were extracted and transeripted from bone marrow cells and normal skin cells in 222 newly diagnosed AML patients. The primers were designed for FANCJ gene coding region, the mutations of FANCJ gene coding region in AML patients as well as the mutations of FANCJ gene in mucous membrane epethelia in patients were detected by PCR and sanger seguencing; the evolutionary conservation of FANCJ mutation in different organisms was analyzed by NCBI Blast online bioinformaties software. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.006DOI Listing
April 2019
2 Reads

[Analysis of Unfavorable Prognosis Gene Markers in Patients with Acute Myeloid Leukemia by Multiomics].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):331-338

School of Management, Shanxi Medical University, Taiyuan 030001, Shanxi Province,China,E-mail:

Objective: To analyze the molecular markers associated with occurrence, development and poor prognosis of acute myeloid leukemia (AML) by using the data of GEO and TCGA database, as well as multiomics analysis.

Methods: The transcriptome data meeting requirements were down-loaded from GEO database, the differentially expressed genes were screened by using the R language limma package, and the GO function enrichment analysis and KEGG pathway analysis were performed for differentially expressed genes, at the same time, the protein interaction network was contracted by using STRING database and cytoscape software to screen out the hub gene, then the prognosis analysis was carried out for hub gene by combination with the clinical information affected in TCGA database.

Results: 620 differentially expressed genes were screened out, among which 162 differentially expressed genes were up-regulated, and 458 differentially expressed genes were down-regulated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.004DOI Listing
April 2019
1 Read

[Detection and Analysis of T Lymphocyte Subsets and B Lymphocytes in Patients with Acute Leukemia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):327-330

Department of Hematology, The First Hospital of Lanzhou University, Laznhou 730000, Gansu Province, China.

Objective: To investigate the changes of T lymphocyte subsets, B lymphocyte and NK cells in peripheral blood of patients with acute leukemia at different periods and their significance.

Methods: The peripheral T lymphocyte subsets and B lymphocyte of 95 patients with acute leukemia [(43 cases of acute lymphoblastic leukemia (ALL), 52 cases of acute myeloid leukemia (AML)] and 50 normal people were detected by flow cytometry respectively.

Results: The positive rate of CD3, CD3CD4, CD3CD8, NK cells and CD4/CD8 in the patients with newly diagnosed acute leukemia were significantly lower than those in normal controls (P<0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.003DOI Listing
April 2019
1 Read

[Role of Vascular Niche of Bone Marrow in the Development of MLL-AF9 Induced Acute Myclaid Leukemia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):318-326

State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.E-mail:

Objective: To investigate the role of bone marrow vascular niche in the development of MLL-AF9 acute myeloid leukemia (AML).

Methods: Transplantation experiments were performed to establish non-radiated MLL-AF9 AML model; the half-bone immunofluorescence staining and tile-scan imaging of two-photon confocal microscopy were used to obtain the data of 3 main bone marrow niche cells; flow cytometry analysis was performed to characterize leukemia cells in different anatomical sites.

Results: In the early stage of MLL-AF9 AML, the proportion of leukemia cells in the metaphysis of the femur was significantly higher than that in the diaphysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.002DOI Listing
April 2019
2 Reads

[Bioinformatics Analysis and Verification of Aging-Related Genes of Bone Marrow Mesenchymal Stem Cells in Patients with Acute Myeloid Leukemia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):311-317

State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China,E-mail:

Objective: To screen and verify the differentially expressed genes related with aging of bone marrow mesenchymal stem cells (BM-MSCs) in acute myeloid leukemia (AML) patients by bioinformatics, so as to provide new molecular markers for the research and clinical treatment of AML.

Methods: The gene expression profiling chip related with BM-MSCs in AML patients in our hospital and the gene chip GSE84881 selected from NCBI database GEO were used for data analysis and exploration. The DAVID analysis software was used to perform gene ontology (GO) enrichment analysis and KEGG pathway enrichment analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.001DOI Listing
April 2019
1 Read

The Influence of Proinflammatory Cytokines on Voriconazole Trough Concentration in Patients With Different Forms of Hematologic Disorders.

J Clin Pharmacol 2019 Apr 18. Epub 2019 Apr 18.

School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Even though multiple factors are involved in the high fluctuation of voriconazole (VCZ) plasma concentration, little is known regarding the influence of proinflammatory cytokines on VCZ concentration. The aim of this study was to investigate the influence of proinflammatory cytokines, namely, interleukin (IL)-1β, IL-6, IL-18, interferon-γ, tumor necrosis factor-α, and transforming growth factor (TGF)-β1 on VCZ trough concentration (VCZ-C ) in Chinese patients with different forms of hematologic disorders. A total of 250 plasma samples from 113 patients were analyzed for VCZ-C and proinflammatory cytokines using a validated liquid chromatography-tandem mass spectrometry and enzyme-linked immunosorbent assay methods, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1422DOI Listing
April 2019
1 Read

Variant allele frequencies do not correlate well with myeloblast counts in a clinically validated gene sequencing panel for routine acute myeloid leukemia workup.

Leuk Lymphoma 2019 Apr 18:1-8. Epub 2019 Apr 18.

a Department of Pathology and Laboratory Medicine , Dartmouth-Hitchcock Medical Center One Medical Center Drive , Lebanon , NH , USA.

Next generation sequencing (NGS) has introduced new types of data, such as variant allele frequencies (VAFs), into the workup of acute myeloid leukemias (AML). There is interest in using NGS to prognosticate disease behavior and monitor residual disease, but the attribution of sequencing data entirely to the leukemic clone may be confounded by VAF contribution from background non-leukemic populations and undetected copy number aberrations. Sixty-eight patients with AML were evaluated by a clinically validated gene sequencing panel at our institution from 2015 to 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1587757DOI Listing
April 2019
1 Read

FLT3 inhibitor quizartinib (AC220).

Leuk Lymphoma 2019 Apr 18:1-11. Epub 2019 Apr 18.

a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.

Acute myeloid leukemia (AML) is a heterogeneous disease and remains a therapeutic challenge. Cytogenetics is a well-established prognostic factor. Recent discovery of molecular mutations has gained momentum with some being potential therapeutic targets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1602263DOI Listing
April 2019
1 Read

High expression of miR-338 is associated with poor prognosis in acute myeloid leukemia undergoing chemotherapy.

J Cell Physiol 2019 Apr 17. Epub 2019 Apr 17.

Blood Diseases Institute, Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, Jiangsu, China.

Acute myeloid leukemia (AML) is a heterogeneous disease with unfavorable outcomes. MicroRNAs (miRNAs) are important regulators and prognostic factors involved in AML. To determine the clinical role of miR-338 in AML, a total of 164 adults with de novo AML were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.28676DOI Listing
April 2019
1 Read

Retroperitoneal Hematoma after Bone Marrow Biopsy: The First Cut Should Not Be the Deepest.

Oncol Res Treat 2019 Apr 17;42(5):279-284. Epub 2019 Apr 17.

Department of Internal Medicine II, Asklepios Clinic Uckermark, Schwedt, Germany,

Bone marrow biopsies are standard hematology procedures. We report the case of a patient with acute myeloid leukemia who developed retroperitoneal hematoma after the procedure. The bleeding was stopped with endovascular embolization and coiling. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/499743
Publisher Site
http://dx.doi.org/10.1159/000499743DOI Listing
April 2019
3 Reads

Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.

N Engl J Med 2019 04;380(16):1525-1534

From the Departments of Bone Marrow Transplantation and Cellular Therapy (E.M., B.T., W.J., S.G.), Hematology (S.Z., Z.M., J.C., J.D., X.T., B.Y.R., M.J.W., B.P.S.), Therapeutics Production and Quality (T.L., M.M.M.), Immunology (H.A., B.Y.), Pharmaceutical Sciences (S.J.C.), Biostatistics (G.K., C.L.), and Infectious Diseases (G.M.), St. Jude Children's Research Hospital, Memphis, TN; the Allergy and Clinical Immunology Division, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru (J.C.A.B.); the Department of Pediatrics, Allergy-Immunology Division, Children's Hospital Los Angeles, Los Angeles (J.A.C.), and the Department of Pediatrics, Division of Pediatric Allergy-Immunology-Bone Marrow Transplantation, University of California, San Francisco (UCSF) Benioff Children's Hospital, San Francisco (J.R.L.-B., J.M.P., M.J.C.) - both in California; the Department of Pediatrics, Pediatric Allergy and Immunology, University of New Mexico, Albuquerque (E.D.); University of Oklahoma Health Sciences Center, Tulsa (J.T.L.); Departamento de Pediatria da Universidade de Taubaté, Conselho Nacional de Medicina, São Paulo (A.C.M.A.); Copperfield Childcare, Claremont, South Africa (H.W.); and the Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD (S.S.D.R., H.L.M.).

Background: Allogeneic hematopoietic stem-cell transplantation for X-linked severe combined immunodeficiency (SCID-X1) often fails to reconstitute immunity associated with T cells, B cells, and natural killer (NK) cells when matched sibling donors are unavailable unless high-dose chemotherapy is given. In previous studies, autologous gene therapy with γ-retroviral vectors failed to reconstitute B-cell and NK-cell immunity and was complicated by vector-related leukemia.

Methods: We performed a dual-center, phase 1-2 safety and efficacy study of a lentiviral vector to transfer complementary DNA to bone marrow stem cells after low-exposure, targeted busulfan conditioning in eight infants with newly diagnosed SCID-X1. Read More

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1815408
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1815408DOI Listing
April 2019
6 Reads

Leveraging Single-Cell RNA Sequencing Experiments to Model Intratumor Heterogeneity.

JCO Clin Cancer Inform 2019 Apr;3:1-10

1 All authors: Moffitt Cancer Center and Research Institute, Tampa, FL.

Purpose: Many cancers can be treated with targeted therapy. Almost inevitably, tumors develop resistance to targeted therapy, either from pre-existence or by evolving new genotypes and traits. Intratumor heterogeneity serves as a reservoir for resistance, which often occurs as a result of the selection of minor cellular subclones. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/CCI.18.00074DOI Listing
April 2019
1 Read

Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.

Genes Chromosomes Cancer 2019 Apr 17. Epub 2019 Apr 17.

MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377 Munich, Germany.

Deletions in the long arm of chromosome 7 (del(7q)) are recurrent cytogenetic aberrations in myeloid neoplasms. They occur either isolated or as part of a complex karyotype and are associated with unfavorable prognosis in certain disease entities. We performed detailed cytogenetic analysis, molecular analysis and array comparative genomic hybridization (aCGH) in a cohort of 81 patients with a variety of myeloid malignancies and del(7q) as sole chromosomal alteration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22761DOI Listing
April 2019
1 Read

Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine.

Cancer Med 2019 Apr 16. Epub 2019 Apr 16.

Université Paris-Saclay, Université Paris-Sud, CESP (Center for Research in Epidemiology and Population Health), Inserm, Team Cancer and Environment, Villejuif, France.

We performed a retrospective analysis of 93 myelodysplastic syndromes (MDS) patients with intermediate 2 or high-risk IPSS score to study the impact of Azacitidine (AZA) relative dose intensity (RDI) <80% on the overall survival (OS). There were 51.6% of patients who had full dose and 48. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2121DOI Listing
April 2019
1 Read

The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation.

Ann Hematol 2019 Apr 16. Epub 2019 Apr 16.

Department of Hematology, Changhai Hospital, The Second Military Medical University, Shanghai, China.

To investigate the effect of chronic graft-versus-host disease (cGVHD) on the outcomes of acute myeloid leukemia (AML) patients who relapsed after allogenic hematopoietic cell transplantation, we performed a retrospective analysis on 218 patients with a median follow-up of 21.4 (3.4-179. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03682-2DOI Listing
April 2019
1 Read

Relapse Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Apparently Due to Somatic Cell Evolution via Epigenetic Variation and Immune Selection.

Authors:
Neil S Greenspan

Pathog Immun 2019 27;4(1):79-84. Epub 2019 Feb 27.

Case Western Reserve University, Cleveland, Ohio.

In this brief commentary, I discuss a recently published study that documents the role of immune escape in relapse of acute myeloid leukemia (AML) after hematopoietic cell transplantation (HCT). Of particular interest, the mechanism identified by the authors for the ability of the malignant cells to evade destruction by host T cells is the loss of cell surface expression of HLA class II molecules based on processes other than mutation. The authors labeled this mechanism for altered cell surface display of HLA class II antigens "epigenetic. Read More

View Article

Download full-text PDF

Source
https://paijournal.com/index.php/paijournal/article/view/285
Publisher Site
http://dx.doi.org/10.20411/pai.v4i1.285DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423549PMC
February 2019
2 Reads

The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients.

Cancer Cell Int 2019 4;19:83. Epub 2019 Apr 4.

1Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy.

Background: In addition to morphological and cytogenetic features, acute myeloid leukemias are characterized by mutations that can be used for target-therapy; also the minimal/measurable residual disease (MRD) could be an important prognostic factor. The purpose of this retrospective study was to investigate if somatic mutations could represent an additional prognostic value in respect of MRD alone.

Method: At baseline, 98 patients were tested for , , and for expression; 31 for , , , , -, , -, , and . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-019-0807-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449954PMC
April 2019
1 Read

CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML.

Nat Chem Biol 2019 May 15;15(5):529-539. Epub 2019 Apr 15.

Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.

Understanding the mechanism of small molecules is a critical challenge in chemical biology and drug discovery. Medicinal chemistry is essential for elucidating drug mechanism, enabling variation of small molecule structure to gain structure-activity relationships (SARs). However, the development of complementary approaches that systematically vary target protein structure could provide equally informative SARs for investigating drug mechanism and protein function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41589-019-0263-0DOI Listing
May 2019
1 Read

A Phase 1/2 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed/ Refractory Acute Myeloid Leukemia.

Clin Cancer Res 2019 Apr 16. Epub 2019 Apr 16.

Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute.

Purpose: The prognosis of patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) remains poor and novel therapies are needed. The proteasome pathway represents a potential therapeutic target. A phase 1 trial of the second generation proteasome inhibitor, ixazomib in combination with MEC (mitoxantrone, etoposide, and cytarabine) was conducted in patients with R/R AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3886DOI Listing
April 2019
1 Read

Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.

BMC Cancer 2019 Apr 16;19(1):358. Epub 2019 Apr 16.

Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea.

Background: Micafungin is a well-tolerated and effective prophylactic antifungal agent used in hematologic diseases. In this prospective trial, we evaluated the efficacy and safety of prophylactic micafungin during first induction chemotherapy in patients with acute leukemia. We also compared outcomes of prophylactic micafungin with those of prophylactic posaconazole in acute myeloid leukemia (AML). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5557-9DOI Listing
April 2019
2 Reads

Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML.

Leuk Lymphoma 2019 Apr 17:1-8. Epub 2019 Apr 17.

a TIMM Laboratory , Sahlgrenska Cancer Center, Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.

Consolidation chemotherapy in acute myeloid leukemia (AML) aims at eradicating residual leukemic cells and mostly comprises high-dose cytarabine with or without the addition of anthracyclines, including daunorubicin. Immunogenic cell death (ICD) may contribute to the efficacy of anthracyclines in solid cancer, but the impact of ICD in AML is only partly explored. We assessed aspects of ICD, as reflected by calreticulin expression, in primary human AML blasts and observed induction of surface calreticulin upon exposure to daunorubicin but not to cytarabine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1599110DOI Listing
April 2019
1 Read

Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia.

Cancer Cell 2019 Apr;35(4):677-691.e10

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of the Chinese Academy of Sciences, Beijing 100049, China. Electronic address:

FTO, an mRNA N-methyladenosine (mA) demethylase, was reported to promote leukemogenesis. Using structure-based rational design, we have developed two promising FTO inhibitors, namely FB23 and FB23-2, which directly bind to FTO and selectively inhibit FTO's mA demethylase activity. Mimicking FTO depletion, FB23-2 dramatically suppresses proliferation and promotes the differentiation/apoptosis of human acute myeloid leukemia (AML) cell line cells and primary blast AML cells in vitro. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108193015
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2019.03.006DOI Listing
April 2019
12 Reads

γ-Catenin-Dependent Signals Maintain BCR-ABL1 B Cell Acute Lymphoblastic Leukemia.

Cancer Cell 2019 Apr;35(4):649-663.e10

Department of Oncology UNIL CHUV, University of Lausanne, Epalinges, Switzerland. Electronic address:

The BCR-ABL1 fusion protein is the cause of chronic myeloid leukemia (CML) and of a significant fraction of adult-onset B cell acute lymphoblastic leukemia (B-ALL) cases. Using mouse models and patient-derived samples, we identified an essential role for γ-catenin in the initiation and maintenance of BCR-ABL1 B-ALL but not CML. The selectivity was explained by a partial γ-catenin dependence of MYC expression together with the susceptibility of B-ALL, but not CML, to reduced MYC levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.03.005DOI Listing
April 2019
1 Read

The Yin and Yang of RNA Methylation: An Imbalance of Erasers Enhances Sensitivity to FTO Demethylase Small-Molecule Targeting in Leukemia Stem Cells.

Cancer Cell 2019 Apr;35(4):540-541

Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA. Electronic address:

A prevalent eukaryotic N-methyladensosine (mA) post-transcriptional mark can be "erased" by the mA demethylase FTO, which is commonly deregulated in acute myeloid leukemia (AML). In this issue of Cancer Cell, Huang et al. design small-molecule FTO inhibitors, FB23 and FB23-2, and demonstrate their potent inhibitory impact in AML models. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108193015
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2019.03.011DOI Listing
April 2019
2 Reads

microRNA-1225 inhibit apoptosis of pancreatic cancer cells via targeting JAK1.

Cell Cycle 2019 Apr 16. Epub 2019 Apr 16.

d Department of Emergency Surgery , Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022 , China .

The microRNA miRNA-1225-5p (miR-1225) is known as an essential modulator of the development of multiple cancers and other biological reactions. However, the understanding of its contribution in pancreatic cancer (PC) is insufficient. The effects of miR-1225 on PC cell survival and tumorigenesis in vivo as well as on the modulation of cell apoptosis were investigated. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/15384101.2019.1
Publisher Site
http://dx.doi.org/10.1080/15384101.2019.1608127DOI Listing
April 2019
2 Reads